Skip to main content
OnTheRiceSEE THE WORLD EARLY.
Search the world…
OnTheRice’s Emerging DataInvestment

GE HealthCare’s supply purchase still depends on outside customers

By OnTheRice · Sources and limitations · Report a correction

BULLISHHorizon24H
Probability Not recorded

Buying SOFIE would add manufacturing control while keeping outside partners and customers. Delivery reliability and customer retention are linked tests for the planned investment.

Current priceNot available
24-hour changeNot available

Source confidenceNot assessed

Published
Check time

What’s changing?

Fluorine-18 tracers lose half their radioactivity in about 110 minutes, making nearby, reliable supply important. GE HealthCare says it will retain other manufacturing partners and SOFIE will keep supplying other providers.

Key points

  • Buying SOFIE would add manufacturing control while keeping outside partners and customers.
  • Delivery reliability and customer retention are linked tests for the planned investment.

What could change this view?

  • The deal has not closed. FAPI-74 remains in Phase III testing; approval and improved margins are unproved.

Bottom line

More likely direction: BULLISH over the next 24 hours.

This is based on the information recorded with this signal.

How likely is this call? · Three frameworks

GE HealthCare (GEHC) · BULLISH

Probability not recorded at publication. This earlier call is preserved without adding a hindsight estimate.

Read the shared method · Read the public probability method

Evidence behind this view

Checks whether separate pieces of evidence support the same view.

Recorded connection

Fluorine-18 tracers lose half their radioactivity in about 110 minutes, making nearby, reliable supply important. GE HealthCare says it will retain other manufacturing partners and SOFIE will keep supplying other providers.

We have not established a separate count of independent evidence clusters for this card. Several reports may rely on the same event or data provider.

What past price moves show

Compares today’s price moves with recorded past patterns.

No asset-specific historical pattern test is recorded separately for this card.

Evidence against this view

Shows evidence and risks that could challenge this view.

Recorded opposing evidence and risks

The deal has not closed. FAPI-74 remains in Phase III testing; approval and improved margins are unproved.

Why the direction changed

Explains recorded changes from expecting a rise to expecting a fall, or the reverse.

No documented bullish-to-bearish or bearish-to-bullish change is available for this card. We keep the original call and its time unchanged.

What people say vs the facts

Compares recorded public discussion with checked market facts.

No separate Reddit or public-discussion comparison with verified market data is recorded for this card. We cannot treat social attention as proof of a market move.

How past forecasts performed

Shows recorded forecast results and what they can teach us.

Recorded outcomes for this signal: 0 HIT, 1 MISS, 0 other or pending. These counts are not a forecast probability.

No tested mapping from evidence combinations to future success is recorded for this card. Confidence in sources and past outcomes do not establish a calibrated probability.

MISSHistorical record
Sources, original wording and price checks

Original research record

GE HealthCare agreed to pay US$945 million cash for SOFIE, with closing expected in the first half of 2027. The purchase would add 15 manufacturing sites, 21 cyclotrons and US rights to the experimental FAPI-74 imaging tracer.

Fluorine-18 tracers lose half their radioactivity in about 110 minutes, making nearby, reliable supply important. GE HealthCare says it will retain other manufacturing partners and SOFIE will keep supplying other providers.

OTR’s view: greater supply control does not remove the need to serve outside customers well. Network use and customer retention matter alongside ownership.

Investors: track the close, delivery reliability, use of the sites and retained outside customers.

The deal has not closed. FAPI-74 remains in Phase III testing; approval and improved margins are unproved.

Reliable supply and profitable use of the combined network would support the case.

Customer losses, delivery problems or excessive integration costs would weaken it.

GEHC: BULLISH / WATCH if supply reach produces profitable growth. Watch the expected 2027 close and later operating results. NO ENTRY.

Published

First published through Sites 06 Oct 2026, 12:18:23 SGT

24-hour check

  • GE HealthCare (GEHC)BULLISH ✕ MISS
    Price 1: 65.73000336 USD
    At publication: 06 Oct 2026, 12:18:23 SGT
    Price 2 (+24h): 64.82499695 USD
    At +24h: 07 Oct 2026, 12:18:23 SGT
    Change: -1.377%
    Price 1 source: 06 Oct 2026, 03:59:00 SGT (offset -29963.693075 s)
    Price 2 source: 07 Oct 2026, 03:59:00 SGT (offset -29963.693075 s)    First published through Sites: 06 Oct 2026, 12:18:23 SGT
    Call and evidence

    BULLISH / WATCH

    The price fell between the nearest observations to publication and +24 hours; the bullish direction was incorrect.

    Price series: GEHC · NasdaqGS. Nearest available one-minute candle opening price to each fixed endpoint. Offsets are disclosed; original call and deadline are unchanged.

    Price 1 · at publication

    Exact endpoint: 06 Oct 2026, 12:18:23 SGT

    65.73000336 USD · Nearest intraday candle (approximation)

    Source quote: 65.73000336 USD · 06 Oct 2026, 03:59:00 SGT

    Source observation ↗

    Offset from required time: -29963.693075 seconds. Negative means before; positive means after.

    One-minute candle start; candle opening price. This is an approximation to the requested instant.

    Price 2 · exactly +24 hours

    Exact endpoint: 07 Oct 2026, 12:18:23 SGT

    64.82499695 USD · Nearest intraday candle (approximation)

    Source quote: 64.82499695 USD · 07 Oct 2026, 03:59:00 SGT

    Source observation ↗

    Offset from required time: -29963.693075 seconds. Negative means before; positive means after.

    One-minute candle start; candle opening price. This is an approximation to the requested instant.

    Change: -0.90500641 USD (-1.377%). The price fell between the nearest observations to publication and +24 hours; the bullish direction was incorrect.

    Correction: Owner-requested full recalculation using nearest available intraday prices and disclosed offsets; includes previously settled calls. The previous result remains in the immutable assessment history.

What changed

Recorded public history

Buying SOFIE would add manufacturing control while keeping outside partners and customers. Delivery reliability and customer retention are…

This is the first recorded public view. Further public updates will appear here.

  1. GE HealthCare’s supply purchase still depends on outside customers

    Buying SOFIE would add manufacturing control while keeping outside partners and customers. Delivery reliability and customer retention are linked tests for the planned investment.

    First published by OTR: 6 Oct, 12:18 SGTPublished by OTR: 6 Oct 2026, 12:18 SGT
    GE HealthCare agreement to acquire SOFIE ↗

Why the view changed

This is the first recorded view. Future source-backed updates will appear here.

Evidence, memory & review 1 linked source

What changed: GE HealthCare agreed to pay US$945 million cash for SOFIE, with closing expected in the first half of 2027. The purchase would add 15 manufacturing sites, 21 cyclotrons and US rights to the experimental FAPI-74 imaging tracer.

Named assets or actors: GE HealthCare (GEHC)

Directional takeaway: BULLISH / WATCH

OTR reasoning: Fluorine-18 tracers lose half their radioactivity in about 110 minutes, making nearby, reliable supply important. GE HealthCare says it will retain other manufacturing partners and SOFIE will keep supplying other providers.

Counterpoint: The deal has not closed. FAPI-74 remains in Phase III testing; approval and improved margins are unproved.

Source trail

Review status: APPROVED

No score or probability is presented.